Form 4: Evommune CFO Executes Stock Option Exercise and Sale

Evommune CFO Kyle Carver exercised 15,000 stock options and sold 18,175 shares of common stock under a 10b5-1 trading plan.

Summary

• CFO Kyle Carver exercised 15,000 stock options at a strike price of $2.99 per share.
• Following the exercise, the CFO sold 18,175 shares of common stock at a weighted average price of $22.84 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2026.
• The CFO's direct beneficial ownership of common stock now stands at 59,335 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the transaction is a routine exercise of equity compensation under a pre-planned 10b5-1 arrangement.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on non-public information.
• The exercise of options at $2.99 and subsequent sale at a weighted average of $22.84 reflects significant value appreciation for the executive.

Negatives

• The sale of shares by a high-level executive, such as the CFO, can sometimes be perceived by the market as a lack of long-term confidence, though this was pre-planned.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market sentiment regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to diversify their personal portfolios and is generally viewed as a neutral event by institutional investors when conducted according to a pre-established schedule.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to mitigate legal risks associated with insider trading.
• The volume of shares sold relative to the executive's total holdings is consistent with typical executive compensation and liquidity management practices.

Stakeholder Impact

• Shareholders should note the reduction in the CFO's direct equity stake, though the sale was pre-planned.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Evommune, EVMN, Insider Trading, CFO, Stock Options, 10b5-1